This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.~The planned enrollment is a maximum enrollment of 40 patients to ensure up to 10 Device Deployed subjects in each arm at one site.~The duration of study participation for each subject is expected to be approximately 60 days.
This study is a prospective, non-randomized, two arm, single-center acute feasibility study assessing safety and performance of the Aria CV Acute PH System in WHO Group 2 and 3 PH patients.